Intra-Arterial Cis-Diamminedichloroplatinum Infusion Treatment for Widespread Hepatocellular Carcinoma.
10.3348/jkrs.1997.37.6.1025
- Author:
Sung Il PARK
1
;
Hee Chul YANG
;
Do Yon LEE
;
Yong Woon SHIM
;
Sang Heum KIM
;
Myeong Jin KIM
;
Jong Tae LEE
;
Hyung Sik YOO
Author Information
1. Department of Diagnostic Radiology, Yonsei University College of Medicine.
- Publication Type:Original Article
- Keywords:
Liver neoplasms, chemotherapeutic infusion;
Liver neoplasms, therapy
- MeSH:
Abdominal Pain;
Acute Kidney Injury;
Carcinoma, Hepatocellular*;
Cisplatin*;
Fever;
Hepatic Artery;
Hepatic Encephalopathy;
Humans;
Infusions, Intra-Arterial;
Retrospective Studies;
Survival Rate
- From:Journal of the Korean Radiological Society
1997;37(6):1025-1031
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To evaluate the therapeutic efficacy of intra-arterial infusion of Cis-Diamminedichloroplatinum (C-DDP) for the treatment of hepatocellular carcinomas with widespread involvement. MATERIALS AND METHODS: We retrospectively analyzed 22 patients who between July 1994 and June 1996 had undergone intra-arterial c-DDP infusion therapy for the treatment of hepatocellular carcinomas with widespread involvement. The hepatomas involved both lobes in ten, portal venous obstructions in fourteen, arterio-portal shunts in nine, and arterio-venous shunts in two. Proper hepatic artery was selected for infusion of 100mg/BSA of C-DDP. The same procedure was repeated every 3 to 4 weeks, and the total number of infusions was 65. On the basis of WHO criteria, response was classified as complete remission, partial remission, stable, or progression of the disease. Six-month and one-year survival rates were estimated, and adverse reactions were evaluated. RESULTS: Complete remission was noted in one patient (4.5%) and partial remission in three (13.6%), while 18 showed no response or progression after treatment. The six month survival rate was 59.1%, and the one-year survival rate was 32.1%. Adverse reactions included nausea/vomiting (59.8%), abdominal pain (9.2%), fever (8.0%), acute renal failure (2.3%) and hepatic encephalopathy (1.1%). These adverse reactions were, however, transient and reversible. CONCLUSION: Although the response rate is not high, intra-arterial C-DDP infusion therapy can be used as an alternative treatment for hepatocellular carcinomas with widespread involvement; adverse reactions are tolerable.
